Characteristics of the patients with SLE, n=240
| Mean (range) or % | |
| Age (years) | 49 (18–88) |
| Women | 86.7% |
| Caucasian ethnicity | 90.4% |
| Disease duration (Years) | 10 (0–45) |
| Prednisolone dosage (mg) | 5.8 (0–60) |
| SLEDAI-2K (score) | 2.9 (0–24) |
| Patients meeting SLICC-12 (%) | 236 (98.3) |
| Patients meeting ACR-82 (%) | 202 (84.0) |
| Fulfilled ACR-82 criteria (n) | 4.7 (3–9) |
| Meeting APS criteria (%) | 17.9% |
| SDI (score) | 1.1 (0–9) |
| ACR-82 criteria | n (%) |
| 1. Malar rash | 104 (43.3) |
| 2. Discoid rash | 39 (16.3) |
| 3. Photosensitivity | 121 (50.4) |
| 4. Oral ulcers | 27 (11.3) |
| 5. Arthritis | 182 (75.8) |
| 6. Serositis | 92 (38.3) |
| 7. Renal disorder | 60 (25.0) |
| 8. Neurological disorder | 12 (5.0) |
| 9. Haematological disorder | 137 (57.1) |
| 10. Immunological disorder | 120 (50.0) |
| 11. IF-ANA | 237 (98.8) |
| SDI ≥1 | n (%) |
| Ocular | 19 (7.9) |
| Neuropsychiatric | 42 (17.5) |
| Renal | 12 (5.0) |
| Pulmonary | 9 (3.8) |
| Cardiovascular | 33 (13.8) |
| Peripheral vascular | 18 (7.5) |
| Gastrointestinal | 5 (2.1) |
| Musculoskeletal | 32 (13.3) |
| Skin | 9 (3.8) |
| Premature gonadal failure | 0 |
| Diabetes mellitus | 10 (4.2) |
| Malignancy | 8 (3.3) |
ACR-82, 1982 American College of Rheumatology; APS, antiphospholipid syndrome; IF-ANA, immunofluorescence microscopy antinuclear antibodies; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC-12, 2012 Systemic Lupus International Collaborating Clinics.